Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2004 2
2005 1
2008 2
2009 4
2010 4
2011 7
2012 10
2013 6
2014 10
2015 15
2016 20
2017 15
2018 17
2019 11
2020 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 30790452

101 results
Results by year
Filters applied: . Clear all
Page 1
Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on 18 F-FDG PET/CT in newly diagnosed patients with diffuse large B-cell lymphoma.
Senjo H, Kanaya M, Izumiyama K, Minauchi K, Hirata K, Mori A, Saito M, Tanaka M, Iijima H, Tsukamoto E, Itoh K, Ota S, Morioka M, Hashimoto D, Teshima T; North Japan Hematology Study Group (NJHSG). Senjo H, et al. Cancer Med. 2019 Mar;8(3):953-962. doi: 10.1002/cam4.1973. Epub 2019 Feb 20. Cancer Med. 2019. PMID: 30790452 Free PMC article.
Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P, Becker S, Toledano MN, Vera P, Desbordes P, Jardin F, Tilly H, Gardin I. Decazes P, et al. Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1672-1679. doi: 10.1007/s00259-018-4041-0. Epub 2018 Apr 28. Eur J Nucl Med Mol Imaging. 2018. PMID: 29705879
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.
Cottereau AS, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H, Jardin F, Becker S. Cottereau AS, et al. Clin Cancer Res. 2016 Aug 1;22(15):3801-9. doi: 10.1158/1078-0432.CCR-15-2825. Epub 2016 Mar 2. Clin Cancer Res. 2016. PMID: 26936916 Free article.
Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.
Toledano MN, Desbordes P, Banjar A, Gardin I, Vera P, Ruminy P, Jardin F, Tilly H, Becker S. Toledano MN, et al. Eur J Nucl Med Mol Imaging. 2018 May;45(5):680-688. doi: 10.1007/s00259-017-3907-x. Epub 2018 Jan 17. Eur J Nucl Med Mol Imaging. 2018. PMID: 29344718
Prognostic impact of serum soluble interleukin-2 receptor level at diagnosis in elderly patients with diffuse large B-cell lymphoma treated with R-CHOP.
Umino K, Fujiwara SI, Minakata D, Yamamoto C, Meguro A, Matsuyama T, Sato K, Ohmine K, Izumi T, Muroi K, Kanda Y. Umino K, et al. Leuk Lymphoma. 2019 Mar;60(3):734-741. doi: 10.1080/10428194.2018.1504939. Epub 2018 Sep 6. Leuk Lymphoma. 2019. PMID: 30188236
Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.
Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, Kim EE, Yoon SS, Chung JK. Shagera QA, et al. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1417-1427. doi: 10.1007/s00259-019-04309-4. Epub 2019 Apr 2. Eur J Nucl Med Mol Imaging. 2019. PMID: 30941463
Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T, Fukuno K, Takahashi T, Kito Y, Takami T, Moriwaki H. Goto N, et al. Ann Hematol. 2012 May;91(5):705-714. doi: 10.1007/s00277-011-1363-4. Epub 2011 Dec 21. Ann Hematol. 2012. PMID: 22183251
101 results
Jump to page